Biocon Biologics has received approval for its cancer drug Abevmy co-developed with Viatris. Abevmy 100 & 400mg , a biosimilar of Bevacizumab has received marketing authorization approval from the European Commission (EC) following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, said the company in a filing to the stock exchange, reports TOI.
Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
